Related Experiment Videos
Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique
Abstract:
In this study we have developed methods for purification of myeloid progenitor cells (CFU-Cs) from normal human bone marrow cells. Bone marrow aspirates were obtained from volunteers, and mononuclear cells (MNCs) were separated by Ficoll-Hypaque gradient centrifugation. T- and B-lymphocytes, monocytes, mature granulocytes, and erythroid precursors were eliminated by an immune-rosette technique using a panel of murine monoclonal antibodies and immunoglobulin (Ig)-coated sheep red blood cells (SRBCs). MNCs were treated with OKT3, B1, M3, Mo5, and EP1 monoclonal antibodies, which are reactive with T cells, B cells, monocytes, granulocytes, and erythroid precursors, respectively. Antibody-treated MNCs were incubated with SRBCs that had been coated with goat antirabbit IgG F(ab')2 and rabbit antimouse Ig for immune rosetting. Rosetted cells were then separated from nonrosetted cells in Ficoll-Hypaque. Nonrosetted cells were, in the second step, treated with an OKIa1 monoclonal antibody and again separated into an Ia+ and Ia- cell fraction by the same manner; 39% +/- 19.2% (mean +/- 1 SD, range 16.3%-75.4%) of CFU-Cs (colonies plus clusters) were recovered in the OKT3-, B1-, M3-, Mo5-, EP1- cell fraction, and the number of CFU-Cs grown in semisolid agar was 149.6 +/- 73.0 (64.0-309.0)/10(4) plated cells in this purified fraction, representing an enrichment of 14.2 +/- 6.4 (6.0-27.3)-fold when compared with unseparated marrow cell fractions. CFU-Cs were enriched 17.7 +/- 8.6 (6.1-28.3)-fold in the Ia+ cell fraction. These purified myeloid precursors would be of value for in-depth studies of the interactions between hematopoietic progenitor cells and regulatory factors that influence their proliferation and differentiation and also of drug metabolism and determinants of cytotoxicity.
Insights
Researchers developed a new method to purify myeloid progenitor cells (CFU-Cs) from human bone marrow. This technique effectively isolates these crucial stem cells for further research into their development and drug interactions.
Area of Science:
- Hematology
- Immunology
- Cell Biology
Background:
- Human bone marrow contains various cell types, including myeloid progenitor cells (CFU-Cs).
- Efficient isolation of CFU-Cs is essential for studying hematopoiesis and cellular interactions.
- Previous methods lacked sufficient specificity and enrichment for CFU-Cs.
Purpose of the Study:
- To develop and validate a robust method for purifying myeloid progenitor cells (CFU-Cs) from normal human bone marrow.
- To achieve significant enrichment of CFU-Cs for subsequent functional and mechanistic studies.
- To provide a purified cell population for investigating regulatory factors and drug effects on myeloid precursors.
Main Methods:
- Mononuclear cells (MNCs) were isolated from bone marrow aspirates using Ficoll-Hypaque gradient centrifugation.
- An immune-rosette technique employing monoclonal antibodies (OKT3, B1, M3, Mo5, EP1) and sheep red blood cells (SRBCs) was used to deplete non-progenitor cells.
- Further purification was achieved by separating Ia+ and Ia- cell fractions using the OKIa1 monoclonal antibody.
Main Results:
- A significant enrichment of CFU-Cs was achieved, with 39% recovery in the depleted fraction.
- The purified fraction showed a 14.2-fold enrichment compared to unseparated bone marrow cells.
- An even higher enrichment of 17.7-fold was observed in the Ia+ cell fraction.
Conclusions:
- The developed immune-rosette and antibody-based method effectively purifies myeloid progenitor cells (CFU-Cs) from human bone marrow.
- This purified CFU-C population is valuable for detailed studies on hematopoietic regulation, proliferation, differentiation, and drug-induced cytotoxicity.
- The method offers a significant advancement in isolating specific hematopoietic stem cell populations for research.